Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Pan, Yunbao ^a,c   Wang, Mengyao ^a   Bu, Xianzhang ^b   Zuo, Yinglin ^b   Wang, Sumei ^a   Wang, Dujuan ^a   Liu, Qing ^a   Su, Bojin ^a   Xu, Tao ^a   Wang, Chunhua ^a   Claret, Francois X ^c,d   Yang, Huiling ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Curcumin; Epstein Barr virus associated malignancy; Jab1 CSN5; Nasopharyngeal carcinoma; Tumorigenesis

Indexed keywords

BINDING PROTEIN; C JUN ACTIVATION DOMAIN BINDING PROTEIN 1; CASPASE 3; CURCUMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; T 83; UNCLASSIFIED DRUG; COPS5 PROTEIN, HUMAN; PEPTIDE HYDROLASE; RADIOSENSITIZING AGENT; SIGNAL PEPTIDE; T83 COMPOUND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NASOPHARYNX CARCINOMA; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RADIOSENSITIVITY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; GENETIC TRANSFECTION; METABOLISM; NASOPHARYNX TUMOR; RADIATION DOSE; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NASOPHARYNGEAL NEOPLASMS; PEPTIDE HYDROLASES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84879472052     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-323     Document Type: Article

References (25)

1. Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol 2012, 22(2):79-86. 10.1016/j.semcancer.2011.12.011, 22245473.
2. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003, 39(15):2121-2135. 10.1016/S0959-8049(03)00367-8, 14522369.
3. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5(5):423-428. 10.1016/S1535-6108(04)00119-9, 15144950.
4. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005, 365(9476):2041-2054. 10.1016/S0140-6736(05)66698-6, 15950718.
5. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 2005, 11(22):8131-8144. 10.1158/1078-0432.CCR-05-1266, 16299246.
6. Qu C, Liang Z, Huang J, Zhao R, Su C, Wang S, Wang X, Zhang R, Lee MH, Yang H. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle 2012, 11(4):785-796. 10.4161/cc.11.4.19228, 3356830, 22374676.
7. Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, Claret FX, Yang H. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res 2012, 72(7):1890-1900. 10.1158/0008-5472.CAN-11-3472, 3460549, 22350412.
8. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene 2013, 32(22):2756-2766. 10.1038/onc.2012.294, 22797071.
9. Pan Y, Claret FX. Targeting Jab1/CSN5 in nasopharyngeal carcinoma. Cancer Lett 2012, 326(2):155-160. 10.1016/j.canlet.2012.07.033, 22867945.
10. Ji JL, Huang XF, Zhu HL. Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med Chem 2012, 12(3):210-218. 10.2174/187152012800228733, 22044005.
11. Yogosawa S, Yamada Y, Yasuda S, Sun Q, Takizawa K, Sakai T. Dehydrozingerone, a Structural Analogue of Curcumin, Induces Cell-Cycle Arrest at the G2/M Phase and Accumulates Intracellular ROS in HT-29 Human Colon Cancer Cells. J Nat Prod 2012, 75(12):2088-2093. 10.1021/np300465f, 23245566.
12. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4(6):807-818. 10.1021/mp700113r, 17999464.
13. Cen L, Hutzen B, Ball S, DeAngelis S, Chen CL, Fuchs JR, Li C, Li PK, Lin J. New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC Cancer 2009, 9:99. 10.1186/1471-2407-9-99, 2674881, 19331692.
14. Debata PR, Castellanos MR, Fata JE, Baggett S, Rajupet S, Szerszen A, Begum S, Mata A, Murty VV, Opitz LM, et al. A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells. Gynecol Oncol 2012, 0090-8258. (0012)00952-00953 [pii]/00910.01016/j.ygyno.02012.00912.00005.
15. Manohar S, Khan SI, Kandi SK, Raj K, Sun G, Yang X, Calderon Molina AD, Ni N, Wang B, Rawat DS. Synthesis, antimalarial activity and cytotoxic potential of new monocarbonyl analogues of curcumin. Bioorg Med Chem Lett 2013, 23(1):112-116. 10.1016/j.bmcl.2012.11.004, 23218718.
16. Li J, Wang Y, Yang C, Wang P, Oelschlager DK, Zheng Y, Tian DA, Grizzle WE, Buchsbaum DJ, Wan M. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol 2009, 76(1):81-90. 10.1124/mol.109.054551, 19395473.
17. Zuo Y, Huang J, Zhou B, Wang S, Shao W, Zhu C, Lin L, Wen G, Wang H, Du J, et al. Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-kappaB and Akt signalling. Eur J Med Chem 2012, 55:346-357.
18. Liu H, Zhou BH, Qiu X, Wang HS, Zhang F, Fang R, Wang XF, Cai SH, Du J, Bu XZ. T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells. Free Radic Biol Med 2012, 53(12):2204-2217. 10.1016/j.freeradbiomed.2012.10.537, 23085518.
19. Qiu X, Du Y, Lou B, Zuo Y, Shao W, Huo Y, Huang J, Yu Y, Zhou B, Du J, et al. Synthesis and Identification of New 4-Arylidene Curcumin Analogues as Potential Anticancer Agents Targeting Nuclear Factor-kappaB Signaling Pathway. J Med Chem 2010, 53(23):8260-8273.
20. Qiu X, Liu Z, Shao WY, Liu X, Jing DP, Yu YJ, An LK, Huang SL, Bu XZ, Huang ZS, et al. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors. Bioorg Med Chem 2008, 16(17):8035-8041. 10.1016/j.bmc.2008.07.054, 18678491.
21. Zhang XC, Chen J, Su CH, Yang HY, Lee MH. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem 2008, 103(4):1219-1230. 10.1002/jcb.21504, 17879958.
22. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371(6495):346-347. 10.1038/371346a0, 8090205.
23. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376(6535):37-43. 10.1038/376037a0, 7596430.
24. Krueger SA, Wilson GD, Piasentin E, Joiner MC, Marples B. The effects of G2-phase enrichment and checkpoint abrogation on low-dose hyper-radiosensitivity. Int J Radiat Oncol Biol Phys 2010, 77(5):1509-1517. 10.1016/j.ijrobp.2010.01.028, 20637979.
25. Fernet M, Megnin-Chanet F, Hall J, Favaudon V. Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity. DNA Repair (Amst) 2010, 9(1):48-57.